A Look at the Latest Occurrences in the Healthcare Sector: Special Research on Sangamo BioSciences,Seattle Genetics, StemCells, Synageva and VBI Vaccines

NEW YORK, February 19, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Sangamo BioSciences (NASDAQ: SGMO), Seattle Genetics (NASDAQ: SGEN), StemCells (NASDAQ: STEM), Synageva (NASDAQ: GEVA), and VBI Vaccines (NASDAQ: VBIV). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

SGMO Research Report: ( http://get.analystsreview.com/pdf/?c=Sangamo%20BioSciences&d=19-Feb-2015&s=SGMO ),

SGEN Research Report: ( http://get.analystsreview.com/pdf/?c=Seattle%20Genetics&d=19-Feb-2015&s=SGEN ),

STEM Research Report: ( http://get.analystsreview.com/pdf/?c=StemCells&d=19-Feb-2015&s=STEM ),

GEVA Research Report: ( http://get.analystsreview.com/pdf/?c=Synageva&d=19-Feb-2015&s=GEVA ),

VBIV Research Report: ( http://get.analystsreview.com/pdf/?c=VBI%20Vaccines&d=19-Feb-2015&s=VBIV ).

============

--

Analyst Update: Presentation of Clinical Data, Financial Results,Clinical Study Commencement, and Sponsorships

Reviewed by: Rohit Tuli, CFA®  

The US stock markets mostly closed lower on Wednesday despite progress in Greece negotiations and dovish Fed minutes. Dow Jones Industrial Average closed down 17.85 points, or 0.10%, at 18,029.85; S&P 500 closed down 0.68 points, or 0.03%, at 2,099.66; Nasdaq closed up 7.10 points, or 0.14%, at 4,906.36. European stocks ended mostly higher and rose to seven-year high amid Greek deal prospects, as Greece is expected to submit a loan request on Thursday to extend a loan agreement for up to six months. The FTSEuroFirst 300 index rose 0.7% to a fresh seven-year high of 1,515.90. On the other hand, most Asian stocks advanced on Wednesday due to investor optimism ahead of a European Central Bank meeting on bailout conditions for Greece, though many markets of the region were shut for the Lunar New Year.

Sangamo BioSciences, Inc. (Sangamo BioSciences) recently presented preclinical data from its In Vivo Protein Replacement Platform (IVPRP) program for the development of proprietary ZFP Therapeutics® for the potential cure of lysosomal storage disorders (LSDs).

Seattle Genetics, Inc. (Seattle Genetics) announced its Q4 and full-year 2014 financial results. For Q4 2014, total revenues came in higher at $74.3 million versus $67.4 million in Q4 2013. Full-year 2014 revenues at $286.8 million also topped prior year top line figure of $269.3 million.

StemCells, Inc. (StemCells) has transplanted the first subject in its Phase II Pathway® Study assessing the efficacy of its proprietary HuCNS-SC® (purified human neural stem cells) platform technology for the treatment of cervical spinal cord injury (SCI).

Synageva BioPharma Corp. (Synageva) has started dosing with SBC-103 in patients with mucopolysaccharidosis IIIB (MPS IIIB) as part of its Phase 1/2 study. The primary endpoint of the trial is safety and tolerability of intravenous administration of SBC-103 in patients with MPS IIIB.

VBI Vaccines Inc. (VBI Vaccines) has announced its sponsorship support of the Utah CMV Council and the End CMV Silence Gala- a fund raiser to be held at the Utah State Capitol Building in Salt Lake City on February 27, 2015. Proceeds from the End CMV Silence Gala will be used to fund a statewide advertising campaign that will help promote cytomegalovirus ("CMV") awareness and prevention.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.